How is Entresto (sacubitril/valsartan) dosed when kidney function is reduced?
Entresto dosing is adjusted based on kidney function, especially for patients with severe renal impairment. The standard starting dose (for adults) is typically 49/51 mg taken twice daily after the initial titration period, but clinicians may start lower in patients with significant kidney problems to reduce risk of low blood pressure and other adverse effects.
For severe renal impairment (commonly defined as eGFR <30 mL/min/1.73m²), the usual approach is to use the lower starting dose (24/26 mg) taken twice daily. Dose titration is then based on tolerance and blood pressure response.
What starting dose is used in severe renal impairment, and when is it increased?
In patients with severe renal impairment, Entresto is generally started at 24/26 mg twice daily. If the patient tolerates it (blood pressure and kidney function remain acceptable), clinicians may consider titrating to 49/51 mg twice daily. How quickly titration happens depends on stability of blood pressure and overall tolerability.
What kidney-related labs and symptoms are monitored during treatment?
When Entresto is used in renal failure, clinicians typically monitor:
- Blood pressure (to watch for hypotension)
- Serum creatinine/eGFR (to detect worsening renal function)
- Potassium (because RAAS-blocking drugs can raise potassium)
Patients are advised to report symptoms that can signal low blood pressure (dizziness, fainting), kidney issues (significant decline in urine output, unusual swelling), or high potassium (muscle weakness, abnormal heart rhythms).
What happens if kidney function worsens after starting Entresto?
If kidney function declines after initiation or up-titration, the next steps often involve reassessing contributing factors (dehydration, interacting drugs, NSAID use), checking potassium, and adjusting the Entresto dose. In some cases, therapy may be paused until the cause is corrected. The key clinical point is that worsening kidney function or dangerous potassium levels generally triggers dose reduction or interruption.
Is Entresto used differently in dialysis patients?
Entresto dosing guidance in end-stage renal disease or dialysis populations can differ from guidance for non-dialysis patients, because clinical trial evidence is more limited in some severely renally impaired groups. In practice, clinicians often use the lowest starting dose and titrate cautiously with close monitoring of blood pressure, potassium, and renal/hemodynamic status.
Are there drugs that commonly interact with Entresto in renal failure?
In patients with renal failure, clinicians pay extra attention to combinations that can increase risk of hypotension, kidney injury, or hyperkalemia. Common examples include:
- Potassium supplements or potassium-sparing agents (risk of hyperkalemia)
- NSAIDs (can worsen kidney function)
- Other RAAS agents or drugs that lower blood pressure (additive hypotension)
If you tell me the patient’s eGFR (or creatinine) and whether they’re on dialysis, I can map the dosing direction more precisely to the renal category.
Source
DrugPatentWatch (helps track product labeling and related regulatory/patent context): https://www.drugpatentwatch.com/